Results 231 to 240 of about 4,701,672 (287)
Difference-Spectrum Completion of Multi-Weight Optical Orthogonal Codes. [PDF]
Park JU, Park SE, Jin D, Chung JH.
europepmc +1 more source
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao +5 more
wiley +1 more source
Thermohydraulic performance prediction of an additively manufactured minichannel gas-to-gas heat exchanger. [PDF]
Choudhary V, A M A, Ranganayakulu C.
europepmc +1 more source
ABSTRACT Background Collaterals are crucial factors that influence the infarct growth rate (IGR). We aimed to determine whether a comprehensive multimodal collateral score (MCS), incorporating collateral assessment at the arterial, tissue, and venous levels, is associated with functional independence and provides incremental prognostic value over ...
Giorgio Busto +12 more
wiley +1 more source
Discrete Equations from BäckLund Transformations of the Fifth Painlevé Equation. [PDF]
Clarkson PA, Dunning C, Mitchell B.
europepmc +1 more source
Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall
ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni +19 more
wiley +1 more source
A fast Chebyshev exponential-integrator solver for stochastic PDEs on bounded domains with non-homogeneous Dirichlet boundary data. [PDF]
Sarker RC, Islam MS, Rahman A.
europepmc +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
Penalised Spline Estimation of Covariate-Specific Time-Dependent ROC Curves. [PDF]
Rodríguez-Álvarez MX, Inácio V.
europepmc +1 more source

